Tag: Boston Scientific

VIRTUS 12-month outcomes presented at LINC: Vici stent meets primary endpoints

New 12-month data from the VIRTUS trial demonstrates that patients who were treated with the Vici Venous Stent system (Boston Scientific) for iliac and femoral...

Boston Scientific announces recommended offer to acquire BTG

Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...

Boston Scientific announces agreement to acquire Veniti

Boston Scientific has signed an agreement to acquire Veniti, a privately-held company in Fremont, USA which developed and commercialised the Vici venous stent system for...

Veniti announces Boston Scientific distribution agreement for Vici venous stent

Boston Scientific will distribute Veniti’s Vici venous stent under a limited global distribution agreement. The terms of the agreement and specific regions and countries...

Endovenous laser therapy of saphenous vein reflux using thulium laser with...

In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to...

Veniti closes on US$25m from Boston Scientific

Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...